您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

中国医药研发对照标品提供商
Non-clinical Research-used
Medicine Sample Provider

当前本网站药物产品种数共 8416 处方药 8043 非处方药 267 保健品/医疗用具 106

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:


QQ客服1:1793093587
QQ客服2:1586083059
QQ客服3:2786706041
QQ客服6:2992753224
QQ客服7:2394834588

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 美国药房
产地国家: 美国
所属类别: 激素内分泌药物->生长激素
处方药:处方药
包装规格: 5毫克/瓶
计价单位:
  点击放大  
生产厂家中文参考译名:
礼来
生产厂家英文名:
LILLY
该药品相关信息网址1:
http://www.rxlist.com/humatrope-drug.htm
该药品相关信息网址2:
http://baike.baidu.com/view/775822.htm?fr=ala0_1
原产地英文商品名:
HUMATROPE 5MG/VIAL
原产地英文药品名:
SOMATROPIN RECOMBINANT
中文参考商品译名:
HUMATROPE 5毫克/瓶
中文参考药品译名:
重组生长激素
原产地国家批准上市年份:
1987/03/08
英文适应病症1:
GH Deficiency of children and adults
英文适应病症2:
Turner Syndrome
临床试验期:
完成
中文适应病症参考翻译1:
儿童及成人内源性生长激素缺乏症
中文适应病症参考翻译2:
特纳综合征
药品信息:

------------------------------------------------------
详细处方信息以本药内容附件PDF文件(2009123022534532.pdf,20125223554734.PDF)的“原文Priscribing Information”为准
------------------------------------------------------
部分中文 HUMATROPE 处方信息(仅供参考)

DRUG DESCRIPTION
Humatrope (somatropin, rDNA origin, for injection) is a polypeptide hormone of recombinant DNA origin. Humatrope
is synthesized in a strain of Escherichia coli that has been modified by the addition of the gene for human GH. The peptide is comprised of 191 amino acid residues and has a molecular weight of about 22,125 daltons. The amino acid sequence of the peptide is identical to that of human GH of pituitary origin.Humatrope is a sterile, white, lyophilized powder intended for subcutaneous or intramuscular administration after reconstitution to its liquid form. Humatrope is a highly purified preparation. Phosphoric acid and/or sodium hydroxide may have been added to adjust the pH. Reconstituted solutions have a pH of approximately 7.5. This product is oxygen sensitive.

INDICATIONS
Pediatric Patients
Growth Hormone Deficiency — Humatrope is indicated for the treatment of pediatric patients who have growth
failure due to inadequate secretion of endogenous growth hormone (GH).
Short Stature Associated with Turner Syndrome — Humatrope is indicated for the treatment of short stature
associated with Turner syndrome.
Idiopathic Short Stature — Humatrope is indicated for the treatment of idiopathic short stature, also called
non-GH-deficient short stature, defined by height SDS ≤ -2.25 and associated with growth rates unlikely to permit attainment of adult height in the normal range, in pediatric patients for whom diagnostic evaluation excludes other causes of short stature that should be observed or treated by other means ; SDS = standard deviation scores.
SHOX Deficiency — Humatrope is indicated for the treatment of short stature or growth failure in children with
short stature homeobox-containing gene (SHOX) deficiency.
Small for Gestational Age — Humatrope is indicated for the treatment of growth failure in children born small
for gestational age (SGA) who fail to demonstrate catch-up growth by age two to four years.

Adult Patients
Humatrope is indicated for the replacement of endogenous GH in adults with GH deficiency who meet either of the
following two criteria:
Adult-Onset (AO): Patients who have GH deficiency, either alone or associated with multiple hormone deficiencies
(hypopituitarism), as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma; or
Childhood-Onset (CO): Patients who were GH deficient during childhood as a result of congenital, genetic,
acquired, or idiopathic causes.

SIDE EFFECTS
Most Serious and/or Most Frequently Observed Adverse Reactions
This list presents the most seriousa and/or most frequently observedb adverse reactions during treatment with
somatropin (including events observed in patients who received brands of somatropin other than Humatrope):
•aSudden death in pediatric patients with Prader-Willi syndrome who had risk factors including severe obesity,
history of upper airway obstruction or sleep apnea and unidentified respiratory infection .
•aIntracranial tumors, in particular meningiomas, in teenagers/young adults treated with radiation to the head
for a first neoplasm who subsequently receive somatropin .
•a,bGlucose intolerance including impaired glucose tolerance/impaired fasting glucose as well as overt diabetes
mellitus .
•aIntracranial hypertension .
•aSignificant diabetic retinopathy.
•aSlipped capital femoral epiphysis in pediatric patients .
•aProgression of preexisting scoliosis in pediatric patients .
•bFluid retention manifested by edema, arthralgia, myalgia, nerve compression syndromes including carpal tunnel
syndrome/paraesthesias .
•aUnmasking of latent central hypothyroidism .
•aInjection site reactions/rashes and lipoatrophy (as well as rare generalized hypersensitivity reactions)

PRECAUTIONS
Acute Critical Illness
Increased mortality in patients with acute critical illness due to complications following open heart surgery,
abdominal surgery or multiple accidental trauma, or those with acute respiratory failure has been reported after treatment with pharmacologic dosesof somatropin [see CONTRAINDICATIONS]. The safety of continuing somatropin treatment in patients receiving replacement doses for approved indications who concurrently develop these illnesses has not been established. Therefore, the potential benefit of treatment continuation with somatropin in patients experiencing acute critical illnesses should be weighed against the potential risk.

Prader-Willi Syndrome in Children
There have been reports of fatalities after initiating therapy with somatropin in pediatric patients with Prader
-Willi syndrome who had one or more of the following risk factors: severe obesity, history of upper airway obstruction or sleep apnea, or unidentified respiratory infection. Male patients with one or more of these factors may be at greater risk than females. Patients with Prader-Willi syndrome should be evaluated for signs of upper airway obstruction and sleep apnea before initiation of treatment with somatropin. If, during treatment with somatropin, patients show signs of upper airway obstruction (including onset of, or increased, snoring) and/or new onset sleep apnea, treatment should be interrupted. All patients with Prader-Willi syndrome treated with somatropin should also have effective weight control and be monitored for signs of respiratory infection, which should be diagnosed as early as possible and treated aggressively [see CONTRAINDICATIONS]. Humatrope is not indicated for the treatment of pediatric patients who have growth failure due to genetically confirmed Prader-Willi syndrome.

Neoplasms
Patients with preexisting tumors or GH deficiency secondary to an intracranial lesion should be examined
routinely for progression or recurrence of the underlying disease process. In pediatric patients, clinical literature has revealed no relationship between somatropin replacement therapy and central nervous system (CNS) tumor recurrence or new extracranial tumors. However, in childhood cancer survivors, an increased risk of a second neoplasm has been reported in patients treated with somatropin after their first neoplasm. Intracranial tumors, in particular meningiomas, in patients treated with radiation to the head for their first neoplasm, were the most common of these second neoplasms. In adults, it is unknown whether there is any relationship between somatropin replacement therapy and CNS tumor recurrence.
Patients should be monitored carefully for any malignant transformation of skin lesions (e.g., changes in pre-
existing cutaneous nevi).

Glucose Intolerance
Treatment with somatropin may decrease insulin sensitivity, particularly at higher doses in susceptible patients.
As a result, previously undiagnosed impaired glucose tolerance and overt diabetes mellitus may be unmasked during somatropin treatment. Therefore, glucose levels should be monitored periodically in all patients treated with somatropin, especially in those with risk factors for diabetes mellitus, such as obesity, Turner syndrome, or a family history of diabetes mellitus. Patients with preexisting type 1 or type 2 diabetes mellitus or impaired glucose tolerance should be monitored closely during somatropin therapy. The doses of antihyperglycemic drugs (e.g., insulin or oral agents) may require adjustment when somatropin therapy is instituted in these patients.

Intracranial Hypertension
Intracranial hypertension (IH) with papilledema, visual changes, headache, nausea, and/or vomiting has been
reported in a small number of patients treated with somatropin products. Symptoms usually occurred within the first eight (8) weeks after the initiation of somatropin therapy. In all reported cases, IH-associated signs and symptoms rapidly resolved after cessation of therapy or a reduction of the somatropin dose. Funduscopic examination should be performed routinely before initiating treatment with somatropin to exclude preexisting papilledema, and periodically during the course of somatropin therapy. If papilledema is observed by funduscopy during somatropin treatment, treatment should be stopped. If somatropin-induced IH is diagnosed, treatment with somatropin can be restarted at a lower dose after IH-associated signs and symptoms have resolved. Patients with Turner syndrome may be at increased risk for the development of IH.

Fluid Retention
Fluid retention during somatropin replacement therapy in adults may frequently occur. Clinical manifestations of
fluid retention are usually transient and dose dependent.
Hypopituitarism
Patients with hypopituitarism (multiple pituitary hormone deficiencies) should have their other hormonal
replacement treatments closely monitored during somatropin treatment.

Hypothyroidism
Undiagnosed/untreated hypothyroidism may prevent an optimal response to somatropin, in particular, the growth
response in children. Patients with Turner syndrome have an inherently increased risk of developing autoimmune thyroid disease and primary hypothyroidism. In patients with GH deficiency, central (secondary) hypothyroidism may first become evident or worsen during somatropin treatment. Therefore, patients treated with somatropin should have periodic thyroid function tests performed, and thyroid hormone replacement therapy should be initiated or appropriately adjusted when indicated.

Slipped Capital Femoral Epiphysis in Pediatric Patients
Slipped capital femoral epiphysis may occur more frequently in patients with endocrine disorders (including
pediatric GH deficiency and Turner syndrome) or in patients undergoing rapid growth. Any pediatric patient with the onset of a limp or complaints of hip or knee pain during somatropin therapy should be carefully evaluated.
Progression of Preexisting Scoliosis in Pediatric Patients
Progression of scoliosis can occur in patients who experience rapid growth. Because somatropin increases growth
rate, patients with a history of scoliosis who are treated with somatropin should be monitored for progression of scoliosis. However, somatropin has not been shown to increase the occurrence of scoliosis. Skeletal abnormalities including scoliosis are commonly seen in untreated patients with Turner syndrome. Scoliosis is also commonly seen in untreated patients with Prader-Willi syndrome. Physicians should be alert to these abnormalities, which may manifest during somatropin therapy.

Otitis Media and Cardiovascular Disorders in Patients with Turner Syndrome
Patients with Turner syndrome should be evaluated carefully for otitis media and other ear isorders, as these
patients have an increased risk of ear and hearing disorders. Somatropin treatment may increase the occurrence of otitis media in patients with Turner syndrome. In addition, patients with Turner syndrome should be monitored closely for cardiovascular disorders (e.g., hypertension, aortic aneurysm or dissection, stroke) as patients with Turner syndrome are also at increased risk for these conditions.

Local and Systemic Reactions
When somatropin is administered subcutaneously at the same site over a long period of time, tissue atrophy may
result. This can be avoided by rotating the injection site [see DOSAGE AND ADMINISTRATION]. As with any protein,  local or systemic allergic reactions may occur. Parents/patients should be informed that such reactions are possible and that prompt medical attention should be sought if allergic reactions occur.
Laboratory Tests
Serum levels of inorganic phosphorus, alkaline phosphatase, parathyroid hormone and IGF-I may increase after
somatropin therapy.

[通用药名]基因重组人生长激素 
[药品成分]本品是由191个氨基酸残基或N端有一甲硫氨酸的192个氨基酸残基组成的蛋白。 
[作用与用途]本品具有与人体生长激素同等的作用,即能促进骨骼、内脏和全身生长,促进蛋白质合成,影响脂肪和矿物质代谢
,在人体生长发育中起着关键性作用。皮下注射约80%被吸收,5小时后达高峰血浓度,t1/2约4小时。主要用于内源性脑垂体生长激素分泌不足而引起的生长障碍、躯体矮小的侏儒症、短小病患儿。此外,尚可用于治疗烧伤、骨折、创伤、出血性溃疡、组织坏死、肌肉萎缩症、骨质疏松等疾病。
[用法与用量]本品给药剂量个体差异很大,采用肌内注射或皮下注射,一般用量为每周0.5—0.7单位/kg或每周12单位/m2,
分6—7次给药。
[注意事项]偶可引进皮肤过敏、注射部位发红和皮下脂肪萎缩、氨基转移酶升高、呕吐及腹痛等。
1.肿瘤患者、糖尿病患者、颅内进行性损伤者禁用。
2. 对脑肿瘤的垂体抹儒病者、心脏或肾脏病者、孕妇和哺乳妇女等慎用。
3.使用前,需对脑垂体功能作详细检查,准确诊断后才能应用。
4.应临用时配制,用注射用水溶解,轻轻摇动,切勿振荡,以免变性。

------------------------------------------------------
详细处方信息以本药内容附件PDF文件(2009123022534532.pdf,20125223554734.PDF)的“原文Priscribing Information”为准
------------------------------------------------------

更新日期: 2012-5-3
附件:
20125223554734.PDF    





2009123022534532.pdf    

 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:info.shijiebiaopin.com@gmail.com, info@shijiebiaopin.com